Amgen: Multiple Strengths, But The Valuation Is A Concern
Portfolio Pulse from
Amgen, a biotechnology leader, is rated as a hold due to its fair valuation and competition from biosimilars. Despite this, it boasts competitive advantages, a robust pipeline, and an attractive dividend yield supported by a 14-year streak of increases.
February 07, 2025 | 9:30 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Amgen is rated as a hold due to its fair valuation and competition from biosimilars, despite its strengths in R&D and distribution. The company's dividend yield remains attractive.
Amgen's fair valuation and competition from biosimilars suggest limited short-term price movement, justifying a hold rating. However, its strong dividend yield and competitive advantages in R&D and distribution provide stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100